Compare Dr. Reddys with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SANOFI INDIA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SANOFI INDIA DR. REDDYS LAB/
SANOFI INDIA
 
P/E (TTM) x 34.8 42.0 83.0% View Chart
P/BV x 4.8 8.5 55.8% View Chart
Dividend Yield % 0.6 1.0 54.6%  

Financials

 DR. REDDYS LAB   SANOFI INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
SANOFI INDIA
Dec-18
DR. REDDYS LAB/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,3636,840 49.2%   
Low Rs2,3524,630 50.8%   
Sales per share (Unadj.) Rs1,054.21,203.1 87.6%  
Earnings per share (Unadj.) Rs121.9165.3 73.8%  
Cash flow per share (Unadj.) Rs190.2209.9 90.6%  
Dividends per share (Unadj.) Rs25.0084.00 29.8%  
Dividend yield (eoy) %0.91.5 59.7%  
Book value per share (Unadj.) Rs938.7963.6 97.4%  
Shares outstanding (eoy) m166.1723.03 721.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.8 56.9%   
Avg P/E ratio x23.434.7 67.5%  
P/CF ratio (eoy) x15.027.3 55.0%  
Price / Book Value ratio x3.06.0 51.1%  
Dividend payout %20.550.8 40.3%   
Avg Mkt Cap Rs m474,831132,078 359.5%   
No. of employees `00021.73.3 655.9%   
Total wages/salary Rs m33,8024,068 830.9%   
Avg. sales/employee Rs Th8,091.08,393.8 96.4%   
Avg. wages/employee Rs Th1,561.31,232.4 126.7%   
Avg. net profit/employee Rs Th935.81,153.0 81.2%   
INCOME DATA
Net Sales Rs m175,17027,708 632.2%  
Other income Rs m6,206897 691.9%   
Total revenues Rs m181,37628,605 634.1%   
Gross profit Rs m24,4216,235 391.7%  
Depreciation Rs m11,3481,027 1,105.0%   
Interest Rs m9837 14,042.9%   
Profit before tax Rs m18,2966,098 300.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,4032,292 -61.2%   
Profit after tax Rs m20,2603,806 532.3%  
Gross profit margin %13.922.5 62.0%  
Effective tax rate %-7.737.6 -20.4%   
Net profit margin %11.613.7 84.2%  
BALANCE SHEET DATA
Current assets Rs m125,99115,922 791.3%   
Current liabilities Rs m72,1416,235 1,157.0%   
Net working cap to sales %30.735.0 87.9%  
Current ratio x1.72.6 68.4%  
Inventory Days Days7364 114.8%  
Debtors Days Days10521 502.1%  
Net fixed assets Rs m83,8547,539 1,112.3%   
Share capital Rs m831230 361.3%   
"Free" reserves Rs m155,15721,962 706.5%   
Net worth Rs m155,98822,192 702.9%   
Long term debt Rs m1,3040-   
Total assets Rs m232,25329,839 778.4%  
Interest coverage x19.6872.1 2.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 81.2%   
Return on assets %9.112.8 71.6%  
Return on equity %13.017.2 75.7%  
Return on capital %12.627.5 45.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,1937,587 1,109.7%   
Fx outflow Rs m39,6167,145 554.5%   
Net fx Rs m44,577442 10,085.3%   
CASH FLOW
From Operations Rs m29,8413,739 798.1%  
From Investments Rs m-4,923-731 673.5%  
From Financial Activity Rs m-25,159-1,972 1,275.8%  
Net Cashflow Rs m-2661,036 -25.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.4 14.4 37.5%  
FIIs % 35.3 14.6 241.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 15,184 499.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 5, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AJANTA PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS